1. A Randomized Trial of Bictegravir or Dolutegravir with Emtricitabine and Tenofovir Alafenamide (F/TAF) Followed by Open Label Switch to Bictegravir/F/TAF Fixed Dose Combination. (4th October 2017) Authors: Sax, Paul E; Dejesus, Edwin; Crofoot, Gordon; Ward, Douglas; Benson, Paul; Wei, Lilian; White, Kirsten; Collins, Sean; Martin, Hal; Cheng, Andrew; Quirk, Erin Journal: Open forum infectious diseases Issue: Volume 4(2017)Supplement 1 Page Start: S426 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1–Infected Adults. (1st May 2017) Authors: Gallant, Joel E.; Thompson, Melanie; DeJesus, Edwin; Voskuhl, Gene W.; Wei, Xuelian; Zhang, Heather; White, Kirsten; Cheng, Andrew; Quirk, Erin; Martin, Hal Journal: Journal of acquired immune deficiency syndromes Issue: Volume 75:Number 1(2017) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial. Issue 4 (April 2017) Authors: Sax, Paul E; DeJesus, Edwin; Crofoot, Gordon; Ward, Douglas; Benson, Paul; Dretler, Robin; Mills, Anthony; Brinson, Cynthia; Peloquin, Julie; Wei, Xuelian; White, Kirsten; Cheng, Andrew; Martin, Hal; Quirk, Erin Journal: Lancet Issue: Volume 4:Issue 4(2017) Page Start: e154 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Issue 10107 (4th November 2017) Authors: Gallant, Joel; Lazzarin, Adriano; Mills, Anthony; Orkin, Chloe; Podzamczer, Daniel; Tebas, Pablo; Girard, Pierre-Marie; Brar, Indira; Daar, Eric S; Wohl, David; Rockstroh, Jürgen; Wei, Xuelian; Custodio, Joseph; White, Kirsten; Martin, Hal; Cheng, Andrew; Quirk, Erin Journal: Lancet Issue: Volume 390:Issue 10107(2017) Page Start: 2063 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Lack of Clinically Relevant Effect of Bictegravir (BIC, B) on Metformin (MET) Pharmacokinetics (PK) and Pharmacodynamics (PD). (4th October 2017) Authors: Custodio, Joseph; West, Steve; Yu, Amanda; Martin, Hal; Graham, Hiba; Quirk, Erin; Kearney, Brian Journal: Open forum infectious diseases Issue: Volume 4(2017)Supplement 1 Page Start: S429 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P176 Clinical pharmacology of the HIV integrase strand transfer inhibitor bictegravir. (8th June 2017) Authors: Zhang, Heather; Custodio, Joseph; Wei, Xuelian; Wang, Hui; Wu, Amanda; Ling, John; Martin, Hal; Quirk, Erin; Elliott, Cindy; Kearney, Brian Journal: Sexually transmitted infections Issue: Volume 93(2017)Supplement 1 Page Start: A74 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Phase 3 Randomized, Controlled Trial of Switching to Fixed-dose Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) from Boosted Protease Inhibitor-based Regimens in Virologically Suppressed Adults: Week 48 Results. (4th October 2017) Authors: Daar, Eric; DeJesus, Edwin; Ruane, Peter; Crofoot, Gordon; Oguchi, Godson; Creticos, Catherine; Rockstroh, Jurgen K; Molina, Jean-Michel; Koenig, Ellen; Liu, Ya-Pei; Andreatta, Kristen; Graham, Hiba; Cheng, Andrew; Martin, Hal; Quirk, Erin Journal: Open forum infectious diseases Issue: Volume 4(2017)Supplement 1 Page Start: S735 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗